CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025

Core Insights - CytoSorbents Corporation presented a real-world data analysis showing that its blood purification technology significantly reduces severe bleeding and transfusion needs in urgent CABG patients on ticagrelor [1][6] Study Details - The analysis compared two groups: 150 patients using CytoSorbents' device from the STAR Registry and 644 control patients who did not use the device [3][12] - The primary outcome measured was the incidence of severe bleeding as defined by the BARC-4 criteria, which includes intracranial bleeding, re-operation for bleeding, and large transfusion events [12] Results - The use of the device resulted in a reduction of BARC-4 severe bleeding rates to 10.7% compared to 33% in the control group, with a p-value of <0.001 [7][12] - Large transfusion events (≥5 units of blood) were reduced to 6% in the device group versus 27% in the control group, p<0.001 [7][12] - The need for re-operations to control bleeding was 4% in the device group compared to 9.6% in the control group, p=0.02 [7][12] Safety and Efficacy - No device-related adverse events or deficiencies were reported, indicating the device's safety and ease of use in clinical practice [4][12] - The findings support the routine use of CytoSorbents' device in urgent CABG surgeries for patients on blood thinners like ticagrelor [5][12] Company Overview - CytoSorbents Corporation specializes in blood purification technologies aimed at treating life-threatening conditions in intensive care and cardiac surgery [9] - The company's lead product, CytoSorb®, is approved in the EU and distributed in over 70 countries, with over 250,000 devices used to date [10] - CytoSorbents is also developing the DrugSorb™-ATR system for antithrombotic removal, which has received FDA Breakthrough Device Designations [11][13]